Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
4Moving Biotech Starts Phase 2a Knee Osteoarthritis Trial in Canada
Details : 4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits of GLP-1.
Product Name : 4P004
Product Type : Peptide
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Biophytis Inks Contracts in Asia to Expand Presence in the Region
Details : The partnership development strategy in Asia aims to accelerate the deployment of Ruvembri (20-hydroxyecdysone) and support Biophytis in identifying partners for this drug candidate.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
Details : Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biophytis Seeks US FDA Approval to Initiate SARA-31 Phase 3 Study in Sarcopenia
Details : Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biophytis Has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
Details : Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility. It is being developed for ...
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid. Based on the SARA-INT results, Biophytis is now preparing the phase 3 program and associated regulatory agency interactions.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the SARA-INT Phase 2 study is to evaluate the efficacy and safety of Sarconeos (BIO101) in a randomized placebo-controlled study in patients over 65 years suffering from sarcopenia and considered at high risk of mobility disability.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable